Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.
Three analysts polled by FactSet expected 63.09 yen.
Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.
Analysts surveyed by FactSet expected 1.123 trillion yen.
For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments